31 maj: Europa/luk: Tro på irsk "ja" banket ned af USA-tal
01 jun: Selskabernes forventninger - fredag den 1 juni
01-06-2012 00:14:00

UK Regulator Draft Guidance Recommends Bayer's Xarelto For Blood Clots

Relateret indhold
Relateret debat
19 jul - 
Ja de har da lavet to kontrakter - så må vi se med de t..
19 jul - 
ja Bavarian er heldigvis os partner med J&J. De er efte..
19 jul - 
Står der noget i regnskabet omkring udviklingen på Ebol..

FRANKFURT -(Dow Jones)- The U.K. drug regulator has recommended the use of Xarelto, a drug produced by a unit of Bayer AG (BAYN.XE), to treat blood clots, according to draft final guidance published Friday.

The guidance is likely to result in a recommendation from the National Institute for Health and Clinical Excellence, known as NICE, meaning the U.K. public health-care system will offer the drug and pay for it. The draft guidance is now with consultees, who have the opportunity to appeal against it.

"Bayer Healthcare welcomes this draft final appraisal determination recommendation from NICE because it simplifies the treatment of venous blood clot treatment for physicians and their patients," Bayer spokeswoman Astrid Kranz said.

Earlier, NICE had asked Bayer to provide more information on the drug. The move follows a May 22 approval for Xarelto for stroke prevention and systemic embolism in people with atrial fibrillation.

If the final approval is given, Xarelto, also known as Rivaroxaban, may then be offered as an alternative to injectable anticoagulants such as low-molecular-weight heparin or fondaparinux sodium, overlapped with a vitamin-K antagonist, such as warfarin.

It is estimated that there will be over 46,000 cases of acute deep vein thrombosis, or DVT, in England and Wales during 2012, rising to nearly 50,000 by 2016 due in large part to the aging population, NICE said.

"Xarelto is the first only novel oral anticoagulant offering a unique single drug solution for the treatment of DVT in adults," Kranz said.

On May 24, Bayer confirmed it expects peak sales of Xarelto of above EUR2 billion annually. The drug, which is being co-developed by Bayer and U.S. drug maker Johnson & Johnson (JNJ), is a rival of Boehringer Ingelheim GmbH's Pradaxa.

-By Monica Houston-Waesch, Dow Jones Newswires; +49 69 29 725 504; nikki.houston@dowjones.com

(END) Dow Jones Newswires

May 31, 2012 18:14 ET (22:14 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Analytikere: Maersk Line kan stå foran katastrofalt regnskab

29-07-2016 16:20:51
Lave priser og for mange skibe på havene er en hovedpine for rederiet Maersk Line, der formentlig står over for et underskud, når A.P. Møller-Mærsk kommer med r..

Carlsberg/Sydbank: AB Inbev-regnskab er ikke problematisk - NY

29-07-2016 13:54:07
(tilføjet info om fusionen med Sabmiller og lavet mindre justeringer, red.)Der er blandede signaler i regnskabet fra AB Inbev, når det kommer til de markeder, h..

Aktier/middag: Jyske Bank til tops forud for stresstest

29-07-2016 11:38:56
Finansaktierne har vind i sejlene fredag middag, hvor markedet afventer en tilsynsvurdering af status for de største europæiske banker.Det danske aktiemarked li..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Analytikere: Maersk Line kan stå foran katastrofalt regnskab
2
Fredagens aktier: C20 lagde brexit-tab bag sig i juli
3
Sabmiller: Bestyrelse anbefaler købstilbud fra AB Inbev
4
USA: Michigan-indekset stort set som ventet

Relaterede aktiekurser

Johnson & Johnson 125,23 0,6% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
30. juli 2016 15:02:08
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160728.2 - EUROWEB7 - 2016-07-30 15:02:08 - 2016-07-30 15:02:08 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x